Apolipoprotein A-I mimetic peptides inhibit expression and activity of hypoxia-inducible factor-1α in human ovarian cancer cell lines and a mouse ovarian cancer model

Journal of Pharmacology and Experimental Therapeutics

Volumn 342, Issue 2, 2012, Pages 255-262

  Gao, Feng ^a   Chattopadhyay, Arnab ^a   Navab, Mohamad ^a   Grijalva, Victor ^a   Su, Feng ^a   Fogelman, Alan M ^a   Reddy, Srinivasa T ^a   Farias Eisner, Robin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; COBALT CHLORIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INSULIN; LUCIFERASE; LYSOPHOSPHATIDIC ACID; PEPTIDE L 4F; PEPTIDE L 5F; PEPTIDOMIMETIC AGENT; REACTIVE OXYGEN METABOLITE; S6 KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG SCREENING; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OVARY CANCER; OXYGEN CONCENTRATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR VASCULARIZATION;

ANIMALS; APOLIPOPROTEIN A-I; CELL LINE, TUMOR; COBALT; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INSULIN; LYSOPHOSPHOLIPIDS; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; OXYGEN; PEPTIDES; PEPTIDOMIMETICS; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; TRANSCRIPTION, GENETIC;

EID: 84864151705     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.191544     Document Type: Article

References (37)

1. Adams RH and Alitalo K (2007) Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 8:464-478. (Pubitemid 46823443)
2. Belozerov VE and Van Meir EG (2005) Hypoxia inducible factor-1: a novel target for cancer therapy. Anticancer Drugs 16:901-909. (Pubitemid 41416080)
3. Biswas S, Gupta MK, Chattopadhyay D, and Mukhopadhyay CK (2007) Insulin-induced activation of hypoxia-inducible factor-1 requires generation of reactive oxygen species by NADPH oxidase. Am J Physiol Heart Circ Physiol 292:H758-H766.
4. Brunelle JK, Bell EL, Quesada NM, Vercauteren K, Tiranti V, Zeviani M, Scarpulla RC, and Chandel NS (2005) Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. Cell Metab 1:409-414. (Pubitemid 43960624)
5. Cao Z, Fang J, Xia C, Shi X, and Jiang BH (2004) trans-3,4,5′- Trihydroxystibene inhibits hypoxia-inducible factor 1α and vascular endothelial growth factor expression in human ovarian cancer cells. Clin Cancer Res 10:5253-5263. (Pubitemid 39099800)
6. Carmeliet P and Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249-257.
7. Carnesecchi S, Carpentier JL, Foti M, and Szanto I (2006) Insulin-induced vascular endothelial growth factor expression is mediated by the NADPH oxidase NOX3. Exp Cell Res 312:3413-3424. (Pubitemid 44380236)
8. Chandel NS, Vander Heiden MG, Thompson CB, and Schumacker PT (2000) Redox regulation of p53 during hypoxia. Oncogene 19:3840-3848. (Pubitemid 30658974)
9. Chen Q, Olashaw N, and Wu J (1995) Participation of reactive oxygen species in the lysophosphatidic acid-stimulated mitogen-activated protein kinase kinase activation pathway. J Biol Chem 270:28499-28502.
10. Ellis LM and Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8:579-591.
11. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186.
12. Ganapathy E, Su F, Meriwether D, Devarajan A, Grijalva V, Gao F, Chattopadhyay A, Anantharamaiah GM, Navab M, Fogelman AM, et al. (2012) D-4F, an apoA-I mimetic peptide, inhibits proliferation and tumorigenicity of epithelial ovarian cancer cells by up-regulating the antioxidant enzyme MnSOD. Int J Cancer 130: 1071-1081.
13. Gao F, Vasquez SX, Su F, Roberts S, Shah N, Grijalva V, Imaizumi S, Chattopadhyay A, Ganapathy E, Meriwether D, et al. (2011) L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways. Integr Biol (Camb) 3:479-489.
14. Getz GS, Wool GD, and Reardon CA (2009) Apoprotein A-I mimetic peptides and their potential anti-atherogenic mechanisms of action. Curr Opin Lipidol 20:171-175.
15. Griguer CE, Oliva CR, Kelley EE, Giles GI, Lancaster JR Jr, and Gillespie GY (2006) Xanthine oxidase-dependent regulation of hypoxia-inducible factor in cancer cells. Cancer Res 66:2257-2263.
16. Guzy RD, Hoyos B, Robin E, Chen H, Liu L, Mansfield KD, Simon MC, Hammerling U, and Schumacker PT (2005) Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab 1:401-408. (Pubitemid 43960623)
17. Guzy RD and Schumacker PT (2006) Oxygen sensing by mitochondria at complex III: the paradox of increased reactive oxygen species during hypoxia. Exp Physiol 91:807-819. (Pubitemid 44266577)
18. Hanahan D and Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364. (Pubitemid 26272076)
19. Kozak KR, Amneus MW, Pusey SM, Su F, Luong MN, Luong SA, Reddy ST, and Farias-Eisner R (2003) Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc Natl Acad Sci U S A 100:12343-12348. (Pubitemid 37271562)
20. Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S, and Farias-Eisner R (2005) Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 5:4589-4596. (Pubitemid 41739936)
21. Kruger AL, Peterson S, Turkseven S, Kaminski PM, Zhang FF, Quan S, Wolin MS, and Abraham NG (2005) D-4F induces heme oxygenase-1 and extracellular superoxide dismutase, decreases endothelial cell sloughing, and improves vascular reactivity in rat model of diabetes. Circulation 111:3126-3134. (Pubitemid 40847791)
22. Lee J, Park SY, Lee EK, Park CG, Chung HC, Rha SY, Kim YK, Bae GU, Kim BK, Han JW, et al. (2006) Activation of hypoxia-inducible factor-1α is necessary for lysophosphatidic acid-induced vascular endothelial growth factor expression. Clin Cancer Res 12:6351-6358. (Pubitemid 44799704)
23. 2-scavenging effect. Mol Cancer Ther 8:2791-2802.
24. Mansfield KD, Guzy RD, Pan Y, Young RM, Cash TP, Schumacker PT, and Simon MC (2005) Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-α activation. Cell Metab 1:393-399. (Pubitemid 43960625)
25. Navab M, Anantharamaiah GM, Reddy ST, and Fogelman AM (2006) Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention. Nat Clin Pract Cardiovasc Med 3:540-547. (Pubitemid 44445797)
26. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Yu N, Ansell BJ, Datta G, Garber DW, et al. (2005) Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol 25:1325-1331.
27. Pouysségur J, Dayan F, and Mazure NM (2006) Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441:437-443. (Pubitemid 44050138)
28. Pouysségur J and Mechta-Grigoriou F (2006) Redox regulation of the hypoxia-inducible factor. Biol Chem 387:1337-1346. (Pubitemid 44691412)
29. Rafii S, Lyden D, Benezra R, Hattori K, and Heissig B (2002) Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2:826-835. (Pubitemid 37328901)
30. Saunders JA, Rogers LC, Klomsiri C, Poole LB, and Daniel LW (2010) Reactive oxygen species mediate lysophosphatidic acid induced signaling in ovarian cancer cells. Free Radic Biol Med 49:2058-2067.
31. Seeber LM, Horrée N, Vooijs MA, Heintz AP, van der Wall E, Verheijen RH, and van Diest PJ (2011) The role of hypoxia inducible factor-1α in gynecological cancer. Crit Rev Oncol Hematol 78:173-184.
32. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721-732.
33. Shah PK and Chyu KY (2005) Apolipoprotein A-I mimetic peptides: potential role in atherosclerosis management. Trends Cardiovasc Med 15:291-296. (Pubitemid 41612085)
34. Su F, Kozak KR, Imaizumi S, Gao F, Amneus MW, Grijalva V, Ng C, Wagner A, Hough G, Farias-Eisner G, et al. (2010) Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci U S A 107:19997-20002.
35. Su F, Lang J, Kumar A, Ng C, Hsieh B, Suchard MA, Reddy ST, and Farias-Eisner R (2007) Validation of candidate serum ovarian cancer biomarkers for early detection. Biomark Insights 2:369-375.
36. Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza GL, and Van Obberghen E (2002) Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/ target of rapamycin-dependent signaling pathway. J Biol Chem 277:27975-27981. (Pubitemid 34966746)
37. Zhou Q, Liu LZ, Fu B, Hu X, Shi X, Fang J, and Jiang BH (2007) Reactive oxygen species regulate insulin-induced VEGF and HIF-1α expression through the activation of p70S6K1 in human prostate cancer cells. Carcinogenesis 28:28-37. (Pubitemid 44942624)